Waypoint Bio raises $20M series a

◆ Amount

$20M

◆ Announced

1 Jun 2026

◆ Company

◆ Source

◆ The Round

Waypoint Bio raised $20M in series a funding, announced on 1 June 2026, led by Amplify Partners, with participation from General Catalyst, Time BioVentures, Mitsui Global Investments, Lux Capital, Hummingbird Ventures. The round is tracked live by Fusion42 as part of the Raise fund database and the Scout startup database.

◆ About Waypoint Bio

AI-driven cell therapy startup developing in vivo CAR T therapeutics using spatial pooled screening and computer vision. Waypoint Bio is based in United States and currently at series a stage, operating in Digital Health, Biotech.

◆ Investors

◆ Investing funds on Raise

• Lux Capital

◆ Market context

Lux Capital is profiled on Raise, Fusion42's database of venture funds — where each investor's thesis, cheque size and other tracked backings can be followed. This funding event is a citable node in Fusion42's market graph: it links Waypoint Bio's Scout profile to the funds behind the round and to related Wire analysis, and is refreshed from public announcements as the round is confirmed or extended. It is the same live market data Arthur reasons over when benchmarking a founder's own raise against what is closing in the market right now.

◆ Explore the market